Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2024 ▲▼ | Q4 2024 ▲▼ | Change ▲▼ | Q3 2024 ▲▼ | Q4 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Liquidia Corporation(LQDA) | 8,118,592 | 8,118,592 | 0 | $81.19M | $115.53M | 29.26% | +$34.34M |
| Verona Pharma PlcADS | 1,436,878 | 1,436,878 | 0 | $41.34M | $66.73M | 16.90% | +$25.39M |
| Exelixis, Inc.(EXEL) | 1,525,730 | 1,525,730 | 0 | $39.59M | $50.81M | 12.87% | +$11.21M |
| Evolus, Inc.(EOLS) | 2,193,488 | 2,692,388 | +498,900 | $35.53M | $29.72M | 7.53% | -$5.81M |
| Anika Therapeutics Inc | 1,435,130 | 1,435,130 | 0 | $35.45M | $23.62M | 5.98% | -$11.83M |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 2,583,585 | 2,995,932 | +412,347 | $19.64M | $22.53M | 5.71% | +$2.89M |
| Agios Pharmaceuticals, Inc.(AGIO) | 579,717 | 626,280 | +46,563 | $25.76M | $20.58M | 5.21% | -$5.18M |
| Sage Therapeutics Inc | 0 | 3,052,538 | +3,052,538 | $0 | $16.58M | 4.20% | +$16.58M |
| Y-Mabs Therapeutics Inc | 1,195,253 | 1,767,982 | +572,729 | $15.72M | $13.84M | 3.51% | -$1.87M |
| Mineralys Therapeutics, Inc.(MLYS) | 981,155 | 1,011,155 | +30,000 | $11.88M | $12.45M | 3.15% | +$565.5K |
| Merus N V | 0 | 255,000 | +255,000 | $0 | $10.72M | 2.72% | +$10.72M |
| ABIVAX Société AnonymeADS(ABVX) | 0 | 752,167 | +752,167 | $0 | $5.51M | 1.39% | +$5.51M |
| Verrica Pharmaceuticals Inc.(VRCA) | 0 | 7,429,687 | +7,429,687 | $0 | $5.20M | 1.32% | +$5.20M |
| Enanta Pharmaceuticals, Inc.(ENTA) | 322,453 | 184,826 | -137,627 | $3.34M | $1.06M | 0.27% | -$2.28M |
| NovaBridge BiosciencesADS(NBP) | 3,499,330 | 0 | -3,499,330 | $4.34M | $0 | — | -$4.34M |
| Outlook Therapeutics, Inc.(OTLK) | 318,699 | 0 | -318,699 | $1.70M | $0 | — | -$1.70M |